EGFR and neoplasm: After treatment with EGFR-TKIs or PD-1/PD-L1 inhibitors, the levels of various glycerol phospholipids tended to decrease to levels similar to those in the HC group, indicating that these two treatments may block the dysregulation of lipid metabolism in tumor cells to a certain extent to exert antitumor therapeutic effects.